– GERMANY, Bonn – NEUWAY Pharma GmbH, a biotech start-up company focusing on the development of innovative drugs on the basis of its proprietary CNS delivery technology, today announced that it has appointed Dr. Wolfgang Baiker as a new Member of its Advisory Board. NEUWAY Pharma GmbH was founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, and received its series A financing from a syndicate led by Wellington Partners.
Dr. Wolfgang Baiker is a Member of the Board of Managing Directors with responsibility for Biopharmaceuticals and Operations at Boehringer Ingelheim, Ingelheim, Germany, the largest privately-owned pharmaceutical company and one of the top 20 pharmaceutical companies worldwide. In this position, which he has held since June 2013, he is responsible for biopharmaceuticals and production globally at the world’s second largest producer of biological molecules. During his 25 years with Boehringer Ingelheim, Dr. Baiker held a number of different key positions including Global Head of Development and Global Head of Project Management. Dr. Baiker holds a Doctorate in Medicine from the University of Ulm and an MBA from Pace University, New York.
Dr. Stephan Rapp, CEO and Managing Director at NEUWAY, commented: “We are highly honored to announce the recruitment of Dr. Wolfgang Baiker as a new Member of our Advisory Board. Dr. Baiker is one of the most successful and experienced managers in the area of development and production of innovative drugs in Germany. With this board position he is committing a considerable amount of his time to this project which has outstanding potential in the field of neurology.”
Dr. Rainer Strohmenger, Chairman at NEUWAY and General Partner at lead investor Wellington Partners, added: “Dr. Wolfgang Baiker is an important addition to the Advisory Board of our portfolio company NEUWAY Pharma. He understands the technology and development process as much in detail as one person can. And with his broad clinical expertise and his insights and overview over the activities of a big pharmaceutical company he will be able to add tremendous value to this project.”
About NEUWAY Pharma
NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.
NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated for the last 4 years and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.